
    
      Patients with advanced castration resistant prostate cancer will receive single agent
      Olaparib at a dose of 400mg twice daily, continuously on a 28 day cycle. Olaparib will be
      administered until objective disease progression or unacceptable toxicity or patient
      withdrawal for whatever reason
    
  